BidaskClub upgraded shares of Heron Therapeutics (NASDAQ:HRTX) from a sell rating to a hold rating in a report released on Wednesday.

A number of other brokerages also recently issued reports on HRTX. Cantor Fitzgerald set a $31.00 target price on Heron Therapeutics and gave the stock a buy rating in a research note on Thursday, October 26th. ValuEngine raised Heron Therapeutics from a sell rating to a hold rating in a research note on Thursday, November 30th. Northland Securities initiated coverage on Heron Therapeutics in a research note on Wednesday, September 27th. They issued an outperform rating and a $40.00 target price for the company. Mizuho reaffirmed a buy rating and issued a $28.00 target price on shares of Heron Therapeutics in a research note on Friday, December 8th. Finally, Noble Financial reaffirmed a buy rating and issued a $24.00 target price on shares of Heron Therapeutics in a research note on Friday, October 6th. Two equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The company has an average rating of Buy and a consensus price target of $28.73.

Heron Therapeutics (NASDAQ:HRTX) traded up $0.40 during midday trading on Wednesday, reaching $17.65. The company had a trading volume of 986,200 shares, compared to its average volume of 851,064. Heron Therapeutics has a 1 year low of $12.21 and a 1 year high of $18.40. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.12 and a quick ratio of 2.02.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.77) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.87) by $0.10. Heron Therapeutics had a negative return on equity of 385.11% and a negative net margin of 831.89%. The firm had revenue of $8.57 million during the quarter, compared to the consensus estimate of $8.12 million. sell-side analysts forecast that Heron Therapeutics will post -3.41 earnings per share for the current year.

Institutional investors have recently made changes to their positions in the stock. Legal & General Group Plc boosted its holdings in Heron Therapeutics by 26.6% during the 2nd quarter. Legal & General Group Plc now owns 11,354 shares of the biotechnology company’s stock valued at $157,000 after acquiring an additional 2,383 shares during the period. Quantbot Technologies LP boosted its holdings in Heron Therapeutics by 2,619.6% during the 2nd quarter. Quantbot Technologies LP now owns 12,483 shares of the biotechnology company’s stock valued at $172,000 after acquiring an additional 12,024 shares during the period. Trexquant Investment LP purchased a new position in Heron Therapeutics during the 3rd quarter valued at about $206,000. Jane Street Group LLC purchased a new position in Heron Therapeutics during the 3rd quarter valued at about $223,000. Finally, HighTower Advisors LLC boosted its holdings in Heron Therapeutics by 11.4% during the 2nd quarter. HighTower Advisors LLC now owns 16,584 shares of the biotechnology company’s stock valued at $231,000 after acquiring an additional 1,700 shares during the period. Institutional investors own 98.78% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was originally published by Watch List News and is owned by of Watch List News. If you are viewing this report on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The original version of this report can be accessed at https://www.watchlistnews.com/heron-therapeutics-hrtx-upgraded-by-bidaskclub-to-hold/1776335.html.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.